Patent Assignment
Reel/Frame 029108/0426
Asset Transfer Agreement
Recorded: 2012-10-10
Pages: 86
Assignor
ELAN PHARMA INTERNATIONAL LIMITED
Executed: 2011-08-02
Assignee
EDT PHARMA HOLDINGS LIMITED
MONKSLAND, ATHLONE, COUNTY WESTMEATH, IRELAND
Covered Properties
(25)
Novel Glipizide Compositions
Solid dosage forms comprising pullulan
Application:
10/705,227 →
Publication:
US 2004/0156895
Nanoparticulate meloxicam formulations
Nanoparticulate Megestrol Formulations
Novel compositions of sildenafil free base
Application:
10/895,405 →
Publication:
US 2005/0042177
Compositions comprising antibodies and methods of using the same for targeting nanoparticulate active agent delivery
Application:
10/979,792 →
Publication:
US 2005/0147664
Nanoparticulate megestrol formulations
Application:
11/093,149 →
Publication:
US 2005/0233001
Nanoparticle dispersion containing lactam compound
Application:
11/129,807 →
Publication:
US 2009/0004277
Nanoparticulate Carverdilol Formulations
Nanoparticulate Quinazoline Derivative Formulations
Nanoparticulate aripiprazole formulations
Application:
11/520,058 →
Publication:
US 2007/0148100
Novel mometasone compositions and methods of making and using the same
Application:
11/633,088 →
Publication:
US 2012/0121653
Nanoparticulate Sorafenib Formulations
Application:
11/775,002 →
Publication:
US 2008/0213374
Nanoparticulate posaconazole formulations
Application:
11/802,427 →
Publication:
US 2007/0281011
Low viscosity liquid dosage forms
Application:
11/979,253 →
Publication:
US 2008/0152585
Nanoparticulate Compositions Having Lysozyme as a Surface Stabilizer
Novel nifedipine compositions
Application:
12/292,395 →
Publication:
US 2009/0104273
In Vitro Methods for Evaluating the in Vivo Effectiveness of Dosage Forms of Microparticulate or Nanoparticulate Active Agent Compositions
Reduction of Flake-Like Aggregation in Nanoparticulate Active Agent Compositions
Application:
12/788,196 →
Publication:
US 2010/0316725
Nanoparticulate Meloxicam Formulations
Application:
12/788,203 →
Publication:
US 2010/0297252
Nanoparticulate Megestrol Formulations
Application:
12/826,557 →
Publication:
US 2010/0266705
Liquid Dosage Compositions of Stable Nanoparticulate Active Agents
Application:
13/044,450 →
Publication:
US 2011/0165251
Nanoparticulate Cinacalcet Compositions
Nanoparticulate Stabilized Anti-Hypertensive Compositions
Application:
13/249,048 →
Publication:
US 2012/0076863
Controlled Release Nanoparticulate Compositions
Application:
13/620,570 →
Publication:
US 2013/0011447
Related Assignments
(25)
Other recorded transfers of the patents in this record — the chain of ownership.
Patent Security Agreement (Second Lien)
Sep 29, 2011
From: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 026994/0245 →
Patent Security Agreement (First Lien)
Sep 29, 2011
From: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 026994/0186 →
Change of Name
Jun 20, 2012
From: EDT PHARMA HOLDINGS LIMITED
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 028414/0223 →
Asset Transfer Agreement
Jun 20, 2012
From: ELAN PHARMA INTERNATIONAL LIMITED
To: EDT PHARMA HOLDINGS LIMITED
Reel/Frame 028415/0458 →
Change of Name
Oct 10, 2012
From: EDT PHARMA HOLDINGS LIMITED
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 029104/0071 →
Release by Secured Party (Second Lien)
Oct 12, 2012
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED; ALKERMES CONTROLLED THERAPEUTICS INC.
Reel/Frame 029116/0379 →
Termination and Release of Security Interest in Patents (First Lien)
Feb 4, 2014
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: ALKERMES, INC.; ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 032161/0475 →
Assignment of Assignor's Interest
Jul 8, 2014
From: ALKERMES PHARMA IRELAND LIMITED
To: OTSUKA PHARMACEUTICAL CO., LTD.
Reel/Frame 033264/0140 →
Property Transfer Agreement
Aug 12, 2014
From: ALKERMES PHARMA IRELAND LIMITED
To: ALKERMES SCIENCE ONE LIMITED
Reel/Frame 033522/0048 →
Change of Name
Mar 27, 2015
From: ALKERMES SCIENCE ONE LIMITED
To: DARAVITA LIMITED
Reel/Frame 035279/0701 →
Asset Transfer and License Agreement
Apr 10, 2015
From: ALKERMES PHARMA IRELAND LIMITED
To: DV TECHNOLOGY LLC
Reel/Frame 035410/0001 →
Business Transfer Agreement
Apr 10, 2015
From: DARAVITA LIMITED
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 035409/0831 →
Security Interest
Apr 14, 2015
From: RECRO TECHNOLOGY LLC
To: ORBIMED ROYALTY OPPORTUNITIES II, LP
Reel/Frame 035403/0288 →
Change of Name
Apr 16, 2015
From: DV TECHNOLOGY LLC
To: RECRO TECHNOLOGY LLC
Reel/Frame 035446/0904 →
Release of Security Interest
Apr 27, 2015
From: MORGAN STANLEY SENIOR FUNDING, INC.
To: DARAVITA LIMITED (F/K/A ALKERMES SCIENCE ONE LIMITED, SUCCESSOR IN INTEREST TO ALKERMES PHARMA IRELAND LIMITED)
Reel/Frame 035505/0696 →
Merger
Sep 23, 2016
From: RECRO TECHNOLOGY LLC
To: RECRO GAINESVILLE LLC
Reel/Frame 039841/0365 →
Assignment of Assignor's Interest
Oct 5, 2016
From: RECRO GAINESVILLE LLC
To: RECRO IRELAND LIMITED
Reel/Frame 039946/0789 →
Merger
Jul 21, 2017
From: RECRO TECHNOLOGY LLC
To: RECRO GAINESVILLE LLC
Reel/Frame 043060/0408 →
Assignment of Assignor's Interest
Jul 21, 2017
From: RECRO GAINESVILLE LLC
To: RECRO PHARMA, INC.
Reel/Frame 043067/0111 →
Assignment of Assignor's Interest
Jul 24, 2017
From: RECRO IRELAND LIMITED
To: RECRO PHARMA, INC.
Reel/Frame 043075/0416 →
Release of Security Interest
Nov 17, 2017
From: ORBIMED ROYALTY OPPORTUNITIES II, LP
To: RECRO GAINESVILLE LLC (F/K/A RECRO TECHNOLOGY LLC)
Reel/Frame 044164/0008 →
Assignment of Assignor's Interest
Jan 30, 2020
From: RECRO PHARMA, INC.
To: BAUDAX BIO, INC.
Reel/Frame 051671/0536 →
Security Interest
Jun 10, 2020
From: BAUDAX BIO N.A. LLC; BAUDAX BIO LIMITED; BAUDAX BIO, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 052891/0590 →
Partial Release of Intellectual Property Security Agreement
Mar 29, 2023
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
To: BAUDAX BIO, INC.; BAUDAX BIO N.A. LLC; BAUDAX BIO LIMITED
Reel/Frame 063189/0142 →
Assignment of Assignor's Interest
May 23, 2023
From: BAUDAX BIO, INC.
To: ALKERMES PHARMA IRELAND LIMITED
Reel/Frame 063736/0279 →